Keywords: Progenics Pharma, Molecular Insight Pharma, M&A, Cancer treatments, Azedra, Trofex

Progenics buys Molecular Insight Pharma to expand oncology pipeline

Article | 23 January 2013

USA-based Progenics Pharmaceuticals (Nasdaq: PGNX) revealed yesterday that it has acquired Molecular Insight Pharmaceuticals, a clinical-stage private biotechnology company with ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Molecular Insight Pharmaceuticals

Progenics Pharmaceuticals

Go to company listing

Related Drugs

Azedra

Trofex

Go to drug listing